Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

Similar articles for PubMed (Select 18088084)


Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.

Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J, Chao Q, Jacob S, Turchin H, Gibbs L, Phillips MD, Mudali S, Iacobuzio-Donahue C, Jaffee EM, Moreno M, Pastan I, Sass PM, Nicolaides NC, Grasso L.

Cancer Immun. 2007 Dec 19;7:20.


Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers.

Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, Schweizer C, Weil S, Laheru D.

Clin Cancer Res. 2010 Dec 15;16(24):6132-8. doi: 10.1158/1078-0432.CCR-10-2275. Epub 2010 Oct 29.


Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy.

Hassan R, Schweizer C, Lu KF, Schuler B, Remaley AT, Weil SC, Pastan I.

Lung Cancer. 2010 Jun;68(3):455-9. doi: 10.1016/j.lungcan.2009.07.016. Epub 2009 Sep 9.


Antitumor activity of anti-C-ERC/mesothelin monoclonal antibody in vivo.

Inami K, Abe M, Takeda K, Hagiwara Y, Maeda M, Segawa T, Suyama M, Watanabe S, Hino O.

Cancer Sci. 2010 Apr;101(4):969-74. doi: 10.1111/j.1349-7006.2009.01463.x. Epub 2009 Dec 9.


Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha.

Ebel W, Routhier EL, Foley B, Jacob S, McDonough JM, Patel RK, Turchin HA, Chao Q, Kline JB, Old LJ, Phillips MD, Nicolaides NC, Sass PM, Grasso L.

Cancer Immun. 2007 Mar 9;7:6.


111In-Labeled CHX-A''-DTPA–conjugated MORAb-009, a chimeric monoclonal antibody directed against mesothelin.

Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2012 Jan 10 [updated 2012 Feb 02].


Mesothelin targeted cancer immunotherapy.

Hassan R, Ho M.

Eur J Cancer. 2008 Jan;44(1):46-53. Epub 2007 Oct 22. Review.


The role of mesothelin in tumor progression and targeted therapy.

Tang Z, Qian M, Ho M.

Anticancer Agents Med Chem. 2013 Feb;13(2):276-80. Review.


A novel high-affinity human monoclonal antibody to mesothelin.

Ho M, Feng M, Fisher RJ, Rader C, Pastan I.

Int J Cancer. 2011 May 1;128(9):2020-30. doi: 10.1002/ijc.25557.


Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.

Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, Bera TK, Connor J, Sathyanarayana BK, Lee B, Pastan I, Patankar MS.

Mol Cancer. 2006 Oct 26;5(1):50.


Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma.

Hassan R, Viner JL, Wang QC, Margulies I, Kreitman RJ, Pastan I.

J Immunother. 2000 Jul-Aug;23(4):473-9.


A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity.

Feng Y, Xiao X, Zhu Z, Streaker E, Ho M, Pastan I, Dimitrov DS.

Mol Cancer Ther. 2009 May;8(5):1113-8. doi: 10.1158/1535-7163.MCT-08-0945. Epub 2009 May 5.


Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibody.

Shin IS, Lee SM, Kim HS, Yao Z, Regino C, Sato N, Cheng KT, Hassan R, Campo MF, Albone EF, Choyke PL, Pastan I, Paik CH.

Nucl Med Biol. 2011 Nov;38(8):1119-27. doi: 10.1016/j.nucmedbio.2011.05.003. Epub 2011 Jul 7.


Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models.

Patel SP, Bristol A, Saric O, Wang XP, Dubeykovskiy A, Arlen PM, Morse MA.

Cancer Immunol Immunother. 2013 Jun;62(6):1011-9. doi: 10.1007/s00262-013-1420-z. Epub 2013 Apr 17.


Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.

Golfier S, Kopitz C, Kahnert A, Heisler I, Schatz CA, Stelte-Ludwig B, Mayer-Bartschmid A, Unterschemmann K, Bruder S, Linden L, Harrenga A, Hauff P, Scholle FD, Müller-Tiemann B, Kreft B, Ziegelbauer K.

Mol Cancer Ther. 2014 Jun;13(6):1537-48. doi: 10.1158/1535-7163.MCT-13-0926. Epub 2014 Apr 8.


Evaluation of (111)In labeled antibodies for SPECT imaging of mesothelin expressing tumors.

Misri R, Saatchi K, Ng SS, Kumar U, Häfeli UO.

Nucl Med Biol. 2011 Aug;38(6):885-96. doi: 10.1016/j.nucmedbio.2011.02.013. Epub 2011 Apr 21.


Mesothelin: a new target for immunotherapy.

Hassan R, Bera T, Pastan I.

Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3937-42. Review.


Mesothelin-targeted agents in clinical trials and in preclinical development.

Kelly RJ, Sharon E, Pastan I, Hassan R.

Mol Cancer Ther. 2012 Mar;11(3):517-25. doi: 10.1158/1535-7163.MCT-11-0454. Epub 2012 Feb 17. Review.


Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.

Harding J, Burtness B.

Drugs Today (Barc). 2005 Feb;41(2):107-27. Review.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk